BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 11241573)

  • 1. Bayesian cost-effectiveness analysis from clinical trial data.
    O'Hagan A; Stevens JW; Montmartin J
    Stat Med; 2001 Mar; 20(5):733-53. PubMed ID: 11241573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Bayesian analysis of pharmacoeconomic data from a clinical trial on schizophrenia.
    Petit C; Maccario J
    Stat Med; 2003 Mar; 22(6):1025-39. PubMed ID: 12627416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Bayesian model averaging approach for cost-effectiveness analyses.
    Conigliani C; Tancredi A
    Health Econ; 2009 Jul; 18(7):807-21. PubMed ID: 18792078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Semi-parametric modelling for costs of health care technologies.
    Conigliani C; Tancredi A
    Stat Med; 2005 Oct; 24(20):3171-84. PubMed ID: 15568210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bayesian estimation of cost-effectiveness from censored data.
    Heitjan DF; Kim CY; Li H
    Stat Med; 2004 Apr; 23(8):1297-309. PubMed ID: 15083484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bayesian approaches to multiple sources of evidence and uncertainty in complex cost-effectiveness modelling.
    Spiegelhalter DJ; Best NG
    Stat Med; 2003 Dec; 22(23):3687-709. PubMed ID: 14652869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bayesian cost-effectiveness analysis with two measures of effectiveness: the cost-effectiveness acceptability plane.
    Negrín MA; Vázquez-Polo FJ
    Health Econ; 2006 Apr; 15(4):363-72. PubMed ID: 16259048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Confidence intervals for cost-effectiveness ratios: an application of Fieller's theorem.
    Willan AR; O'Brien BJ
    Health Econ; 1996; 5(4):297-305. PubMed ID: 8880166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness as an outcome in randomized clinical trials.
    Hlatky MA; Owens DK; Sanders GD
    Clin Trials; 2006; 3(6):543-51. PubMed ID: 17170039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost effectiveness of asthma treatment with a breath-actuated inhaler: how has the story changed?
    Haycox A; Featherstone R
    J Med Econ; 2008; 11(3):525-39. PubMed ID: 19450102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An illustration of the modelling of cost and efficacy data from a clinical trial.
    Hahn S; Whitehead A
    Stat Med; 2003 Mar; 22(6):1009-24. PubMed ID: 12627415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An evaluation of the cost-effectiveness of omalizumab for the treatment of severe allergic asthma.
    Sullivan SD; Turk F
    Allergy; 2008 Jun; 63(6):670-84. PubMed ID: 18445184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and analysis issues for economic analysis alongside clinical trials.
    Marshall DA; Hux M
    Med Care; 2009 Jul; 47(7 Suppl 1):S14-20. PubMed ID: 19536012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of omalizumab in patients with severe persistent allergic asthma.
    Brown R; Turk F; Dale P; Bousquet J
    Allergy; 2007 Feb; 62(2):149-53. PubMed ID: 17298423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of early intervention with once-daily budesonide in children with mild persistent asthma: results from the START study.
    Weiss K; Buxton M; Andersson FL; Lamm CJ; Liljas B; Sullivan SD
    Pediatr Allergy Immunol; 2006 May; 17 Suppl 17():21-7. PubMed ID: 16573705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incorporating model uncertainty in cost-effectiveness analysis: a Bayesian model averaging approach.
    Negrín MA; Vázquez-Polo FJ
    J Health Econ; 2008 Sep; 27(5):1250-9. PubMed ID: 18490067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of early treatment for retinopathy of prematurity.
    Kamholz KL; Cole CH; Gray JE; Zupancic JA
    Pediatrics; 2009 Jan; 123(1):262-9. PubMed ID: 19117891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incremental net benefit in randomized clinical trials.
    Willan AR; Lin DY
    Stat Med; 2001 Jun; 20(11):1563-74. PubMed ID: 11391688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Revisiting the cost-effectiveness of omalizumab.
    Campbell JD; Spackman DE; Sullivan SD
    Allergy; 2007 Dec; 62(12):1469. PubMed ID: 17983382
    [No Abstract]   [Full Text] [Related]  

  • 20. Anti-immunoglobulin E therapy with omalizumab for asthma.
    Hendeles L; Sorkness CA
    Ann Pharmacother; 2007 Sep; 41(9):1397-410. PubMed ID: 17698897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.